Prelude Capital Management’s Amgen AMGN Stock Holding History

Prelude Capital Management’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-400	Closed	-$77K	–	1889
2019 Q3	$77K	Buy	+400	New	+$76.8K	﹤0.01%	1035

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Prelude Capital Management's AMGN Position: Q1 2026 in Review

Prelude Capital Management sold out of Amgen (AMGN) in Q1 2026, closing a stake of 647 shares — an estimated $212K sold.

Prelude Capital Management first reported a position in AMGN in Q2 2013 and held it in 24 quarters. The position peaked at $2.37M in Q1 2024. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

Prelude Capital Management reported no remaining Amgen position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 647 Amgen shares in Q1 2026, an estimated $212K.
Prelude Capital Management first reported a position in Amgen in Q2 2013 and held it in 24 quarters.
Prelude Capital Management's Amgen position peaked at $2.37M in Q1 2024.
3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.